Global Human Rabies Immunoglobulin (IM) Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032

Market Overview

According to DIResearch's in-depth investigation and research, the global Human Rabies Immunoglobulin (IM) market size will reach 370.23 Million USD in 2025 and is projected to reach 478.09 Million USD by 2032, with a CAGR of 3.72% (2025-2032). Notably, the China Human Rabies Immunoglobulin (IM) market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.

Research Summary

Human Rabies Immunoglobulin (HRIG) is a specialized immunoglobulin preparation used in the post-exposure prophylaxis of rabies. When an individual is potentially exposed to the rabies virus through bites or scratches from an infected animal, HRIG is administered as a part of the rabies vaccination protocol. HRIG contains a high concentration of rabies antibodies derived from the plasma of individuals previously vaccinated against rabies. The administration of HRIG provides immediate passive immunity by supplying the patient with pre-formed antibodies, offering rapid protection against the virus while the rabies vaccine induces an active immune response. HRIG is typically administered at the site of the wound or exposure and, if possible, infiltrated into and around the wound. It is a crucial component of the rabies post-exposure prophylaxis regimen and is used in conjunction with rabies vaccinations to prevent the onset of rabies in individuals who may have been exposed to the virus.

The major global  manufacturers of Human Rabies Immunoglobulin (IM) include CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Bharat Serum, Shanghai RAAS, VINS, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Human Rabies Immunoglobulin (IM). Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Human Rabies Immunoglobulin (IM) market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Human Rabies Immunoglobulin (IM) market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Human Rabies Immunoglobulin (IM) industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.    

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Human Rabies Immunoglobulin (IM) Include:

CSL Behring

Grifols

Sanofi

Sichuan Yuanda Shuyang

CNBG

Kamada

CBPO

Shuanglin Bio

Weiguang Bio

Bharat Serum

Shanghai RAAS

VINS

Human Rabies Immunoglobulin (IM) Product Segment Include:

ERIG

HRIG

Human Rabies Immunoglobulin (IM) Product Application Include:

Category II Exposure

Category III Exposure

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend

Chapter 2: Global Human Rabies Immunoglobulin (IM) Industry PESTEL Analysis

Chapter 3: Global Human Rabies Immunoglobulin (IM) Industry Porter's Five Forces Analysis

Chapter 4: Global Human Rabies Immunoglobulin (IM) Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis

Chapter 5: Global Human Rabies Immunoglobulin (IM) Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)

Chapter 6: Global Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Forecast by Product Type

Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)

Chapter 8: Industrial Chain Analysis, Human Rabies Immunoglobulin (IM) Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis

Chapter 9: Research Findings and Conclusion

Chapter 10: Methodology and Data Sources